When to Stop Estrace Cream
Estrace cream does not need to be stopped if symptoms persist and there are no contraindications—it can be continued long-term with appropriate monitoring, though the decision to continue should be reassessed at least annually.
Duration of Treatment
The evidence does not support mandatory discontinuation of vaginal estrogen therapy at any specific time point. According to the 2015 Endocrine Society guidelines, the decision to continue menopausal hormone therapy (including vaginal estrogen) should be revisited at least annually, targeting the shortest total duration consistent with treatment goals and evolving risk assessment 1.
Key Considerations for Continuation vs. Discontinuation:
Symptom-Based Approach:
- Vaginal estrogen effectively relieves symptoms (vaginal dryness, dyspareunia, urinary symptoms) within 2-3 weeks, with objective improvements continuing at 12 weeks and maintained to 1 year 1
- If symptoms persist and quality of life remains impaired, continuation is appropriate
- If symptoms have resolved and remain controlled, you may attempt discontinuation or dose reduction
Safety Profile for Long-Term Use:
- Low-dose vaginal estrogen maintains serum estradiol levels within the normal postmenopausal range, suggesting a lower risk profile than systemic estrogen 1
- However, long-term endometrial safety data are lacking, and 1 year is the maximum duration of RCTs 1
- No increased cardiovascular disease or venous thromboembolism risk has been reported with vaginal estrogen 1
Monitoring Requirements for Continued Use
For women continuing beyond 1 year:
- Annual reassessment of treatment necessity, symptom control, and risk-benefit profile 1
- For women at higher risk of endometrial cancer (late menopause, higher BMI, higher dosing), consider:
- Surveillance using transvaginal ultrasound
- Endometrial biopsy if endometrial thickening is present
- Intermittent (possibly annual) progestogen withdrawal to assess endometrial status 1
Discontinuation should occur immediately if:
- Stroke occurs or is suspected 2
- Venous thromboembolism (DVT or PE) occurs or is suspected 2
- Undiagnosed persistent or recurring abnormal genital bleeding develops 2
- Hypercalcemia develops (particularly in patients with breast cancer and bone metastases) 2
- Visual abnormalities occur (sudden vision loss, proptosis, diplopia, papilledema, retinal vascular lesions) 2
- Anaphylactic reaction or angioedema develops 2
Practical Discontinuation Approach
If attempting discontinuation after symptom resolution:
- Use a shared decision-making approach to determine patient preference for gradual taper vs. abrupt discontinuation 1
- Monitor for symptom recurrence
- Reinitiate if symptoms return and significantly impact quality of life
Special Populations
Women with history of breast or endometrial cancer:
- Use shared decision-making with the treating oncologist 1
- Reserve for patients unresponsive to nonhormonal therapies 3
- Available data do not show increased cancer recurrence risk, but evidence is limited 1
Common Pitfalls to Avoid
- Don't arbitrarily discontinue at 1 year if symptoms persist and there are no contraindications—the 1-year mark reflects the maximum RCT duration, not a mandatory stopping point
- Don't continue indefinitely without reassessment—annual evaluation is essential
- Don't ignore breakthrough bleeding—this requires evaluation to rule out endometrial pathology 1
- Don't use systemic-dose vaginal estrogen (e.g., CEE 0.625-2.5 mg daily) without progestogen coverage, as this causes systemic effects 1